Development of Myasthenia Gravis in a Patient with Chronic Myeloid Leukemia during Treatment with Nilotinib

We report on a patient diagnosed with chronic myeloid leukemia (CML) who developed myasthenia gravis while on treatment with nilotinib. Autoimmune disease, including the development of myasthenia gravis, has been described in association with CML as well as the use of tyrosine kinase inhibitors. Sec...

Descripción completa

Detalles Bibliográficos
Autores principales: Sanford, David, MacDonald, Maria, Nicolle, Michael, Xenocostas, Anargyros
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications, Pavia, Italy 2014
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091286/
https://www.ncbi.nlm.nih.gov/pubmed/25013714
http://dx.doi.org/10.4081/hr.2014.5288
_version_ 1782480750692532224
author Sanford, David
MacDonald, Maria
Nicolle, Michael
Xenocostas, Anargyros
author_facet Sanford, David
MacDonald, Maria
Nicolle, Michael
Xenocostas, Anargyros
author_sort Sanford, David
collection PubMed
description We report on a patient diagnosed with chronic myeloid leukemia (CML) who developed myasthenia gravis while on treatment with nilotinib. Autoimmune disease, including the development of myasthenia gravis, has been described in association with CML as well as the use of tyrosine kinase inhibitors. Second generation tyrosine kinase inhibitors are highly effective in the treatment of CML, although can result in adverse effects related to off-target kinase inhibition, and longer term reporting of adverse effects is required.
format Online
Article
Text
id pubmed-4091286
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher PAGEPress Publications, Pavia, Italy
record_format MEDLINE/PubMed
spelling pubmed-40912862014-07-10 Development of Myasthenia Gravis in a Patient with Chronic Myeloid Leukemia during Treatment with Nilotinib Sanford, David MacDonald, Maria Nicolle, Michael Xenocostas, Anargyros Hematol Rep Case Report We report on a patient diagnosed with chronic myeloid leukemia (CML) who developed myasthenia gravis while on treatment with nilotinib. Autoimmune disease, including the development of myasthenia gravis, has been described in association with CML as well as the use of tyrosine kinase inhibitors. Second generation tyrosine kinase inhibitors are highly effective in the treatment of CML, although can result in adverse effects related to off-target kinase inhibition, and longer term reporting of adverse effects is required. PAGEPress Publications, Pavia, Italy 2014-06-19 /pmc/articles/PMC4091286/ /pubmed/25013714 http://dx.doi.org/10.4081/hr.2014.5288 Text en ©Copyright D. Sanford et al. http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Report
Sanford, David
MacDonald, Maria
Nicolle, Michael
Xenocostas, Anargyros
Development of Myasthenia Gravis in a Patient with Chronic Myeloid Leukemia during Treatment with Nilotinib
title Development of Myasthenia Gravis in a Patient with Chronic Myeloid Leukemia during Treatment with Nilotinib
title_full Development of Myasthenia Gravis in a Patient with Chronic Myeloid Leukemia during Treatment with Nilotinib
title_fullStr Development of Myasthenia Gravis in a Patient with Chronic Myeloid Leukemia during Treatment with Nilotinib
title_full_unstemmed Development of Myasthenia Gravis in a Patient with Chronic Myeloid Leukemia during Treatment with Nilotinib
title_short Development of Myasthenia Gravis in a Patient with Chronic Myeloid Leukemia during Treatment with Nilotinib
title_sort development of myasthenia gravis in a patient with chronic myeloid leukemia during treatment with nilotinib
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091286/
https://www.ncbi.nlm.nih.gov/pubmed/25013714
http://dx.doi.org/10.4081/hr.2014.5288
work_keys_str_mv AT sanforddavid developmentofmyastheniagravisinapatientwithchronicmyeloidleukemiaduringtreatmentwithnilotinib
AT macdonaldmaria developmentofmyastheniagravisinapatientwithchronicmyeloidleukemiaduringtreatmentwithnilotinib
AT nicollemichael developmentofmyastheniagravisinapatientwithchronicmyeloidleukemiaduringtreatmentwithnilotinib
AT xenocostasanargyros developmentofmyastheniagravisinapatientwithchronicmyeloidleukemiaduringtreatmentwithnilotinib

Ejemplares similares